awmsg logo



aclidinium bromide (Eklira® Genuair®)


Reference No. 938

Publication date:
31/07/2013


Last review date:
30/08/2016

Appraisal information

aclidinium bromide (Eklira® Genuair®) 322 micrograms inhalation powder


Company: AstraZeneca UK Ltd
BNF category: Respiratory system
NMG meeting date: 10/04/2013
AWMSG meeting date: 08/05/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0813
Ministerial ratification: 29/07/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Aclidinium bromide (Eklira® Genuair®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download